Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026
Same author

Artificial intelligence-enabled liquid biopsy in cancer: a systematic review and meta- analysis of diagnostic performance and biological implications.

Frontiers in oncology·2026
Same author

Corrigendum to "Management of atypical cartilaginous tumors (ACT): An Italian Sarcoma Group (ISG) consensus document" [Crit. Rev. Oncol. Hematol. 223 (2026) 105358].

Critical reviews in oncology/hematology·2026
Same author

Genome-wide SNP-based Profiling of Loss of Heterozygosity Reveals Distinct Molecular Subgroup-specific Patterns in Gastrointestinal Stromal Tumors (GIST).

Laboratory investigation; a journal of technical methods and pathology·2026
Same author

Handling missing modalities in multimodal survival prediction for non-small cell lung cancer.

NPJ digital medicine·2026
Same author

Risk factors and causes of early death in germ cell tumors: a Global Society for Rare GU tumors study.

British journal of cancer·2026

Related Experiment Video

Updated: Jun 13, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

New therapies in soft tissue sarcoma.

Bruno Vincenzi1, Anna Maria Frezza, Daniele Santini

  • 1University Campus Bio-Medico, Medical Oncology, Via Alvaro del Portillo, 200, 00128, Rome, Italy. b.vincenzi@unicampus.it

Expert Opinion on Emerging Drugs
|May 15, 2010
PubMed
Summary

New targeted therapies show promise for improving survival rates in soft tissue sarcoma patients. Clinical trials are crucial for advancing treatment and managing this aggressive cancer.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Related Experiment Videos

Last Updated: Jun 13, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Area of Science:

  • Oncology
  • Sarcoma Research
  • Clinical Therapeutics

Background:

  • Soft tissue sarcomas are rare mesenchymal tumors, comprising less than 1% of adult cancers.
  • Current treatments (surgery, radiotherapy, chemotherapy) yield a 5-year survival rate of only 50-60% for soft tissue sarcoma.
  • Locally advanced and metastatic soft tissue sarcomas present significant treatment challenges.

Purpose of the Study:

  • To review novel molecules under clinical evaluation for soft tissue sarcoma treatment.
  • To analyze the mechanism of action and biological rationale for new targeted therapies.
  • To report safety and efficacy data for emerging soft tissue sarcoma treatments up to 2009.

Main Methods:

  • Literature review of clinical trials and research on soft tissue sarcoma.
  • Analysis of drug mechanisms targeting sarcoma tumorigenesis.
  • Compilation of safety and efficacy data for new therapeutic agents.

Main Results:

  • Summary of current standard treatments for soft tissue sarcoma.
  • Detailed analysis of the development of new targeted therapies.
  • Overview of the state-of-the-art in soft tissue sarcoma drug development.

Conclusions:

  • New biological therapies targeting key points in soft tissue sarcoma tumorigenesis offer improved prognosis.
  • Participation in clinical trials is the optimal management strategy for soft tissue sarcoma patients.
  • Encouraging enrollment in clinical trials is vital for advancing soft tissue sarcoma care.